• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Management of COVID-19 associated coagulopathy in critically ill patients and the risk of acquired von willebrand syndrome

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Jun 2;15(1):19321.
doi: 10.1038/s41598-025-99786-z. Management of COVID-19 associated coagulopathy in critically ill patients and the risk of acquired von willebrand syndrome

Hiroyasu Ishikura[SUP] 1 2 [/SUP], Yuhei Irie[SUP] 3 [/SUP], Maiko Nakashio[SUP] 3 [/SUP], Junichi Maruyama[SUP] 3 [/SUP], Yoshihiko Nakamura[SUP] 3 [/SUP], Takahiro Yamagaito[SUP] 4 [/SUP], Maho Yoshida[SUP] 5 [/SUP], Hiroki Hatomoto[SUP] 6 [/SUP], Shintaro Yamasaki[SUP] 6 [/SUP], Kota Hoshino[SUP] 3 7 [/SUP]



Affiliations
Abstract

This study investigated the interplay between thrombosis and hemorrhage in critically ill COVID-19 patients, particularly those on extracorporeal membrane oxygenation (ECMO). Forty-three mechanically ventilated patients were divided into ECMO (n = 22) and non-ECMO (n = 21) groups. Thrombotic events occurred similarly in both groups (22.7% in ECMO, 28.6% in non-ECMO), both higher than the approximately 5% observed in patients hospitalized with viral respiratory illnesses other than COVID-19. However, bleeding events were significantly more frequent in the ECMO group (72.7%) compared to the non-ECMO group (14.3%) (P < 0.01). ECMO patients showed decreased platelet counts, fibrinogen, von Willebrand factor (VWF) activity using a ristocetin cofactor (VWF: RCo) assay, and developed acquired von Willebrand syndrome (AvWS) (VWF: RCo/VWF antigen (Ag) ratio < 0.7), along with increased D-dimer and lower high-molecular-weight VWF multimers. In contrast, the non-ECMO group showed no significant changes in platelet counts, fibrinogen, VWF: RCo, or D-dimer. Over time, both VWF: Ag and VWF: RCo increased significantly in both groups, but the VWF: RCo/VWF: Ag ratio remained above 0.7, and high-molecular-weight VWF multimers did not change significantly. These findings emphasize the need for vigilance regarding thrombotic and hemorrhagic complications, particularly in ECMO patients, where ECMO-induced shear stress may lead to AvWS, necessitating monitoring of VWF: Ag and VWF: RCo.

Keywords: Acquired von Willebrand syndrome; COVID-19; Coagulopathy; Hemorrhage; Thrombosis.

 
Back
Top Bottom